B
BioSpace
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
0:00-20:23
Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbreaking pancreatic cancer drug; BioNTech suspends a mid-stage trial of its mRNA cancer immunotherapy after a futility analysis; and nine mid-sized biopharma companies join their big pharma peers in President Donald Trump’s Most Favored Nation drug pricing scheme.
Publisher
BioSpace
Published
September 2, 2026
Duration
20 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
B
BioSpace
@biospace
#bmspausedcar #revmedspancreaticcancer #mfndeals #lifesciences
